DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Multiple Sclerosis
  4. Research Highlights/News
  5. 2016 Multiple Sclerosis Research Program

Multiple Sclerosis

NEWS RELEASE

Released: February 18, 2016

Defense Health Program
Department of Defense Multiple Sclerosis Research Program
Funding Opportunities for Fiscal Year 2016 (FY16)

The FY16 Defense Appropriations Act provides $6 million (M) to the Department of Defense Multiple Sclerosis Research Program (MSRP) to support innovative, high-impact multiple sclerosis (MS) research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY16 MSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2016. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government.

Award Mechanism Investigator Eligibility Focus Area Key Mechanism Elements Funding
Pilot Clinical Trial Award Independent investigators at or above the level of Assistant Professor (or equivalent). All applications submitted in this funding opportunity must address the Treatment of MS Symptoms.
  • Symptoms may include: Pain, Fatigue, Cognitive Dysfunction, Visual Impairment, Motor Impairment, Impaired Mobility, Loss of Bladder Control, Sexual Dysfunction, Depression, and Anxiety.
Note: Studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding.
  • Supports early-phase, proof-of-principle clinical trials to investigate hypothesis-based, innovative interventions that have the potential to result in a profound impact on the management of multiple sclerosis (MS).
  • Pre-application submission is required; application submission is by invitation only.
  • Scientific rationale and/or preliminary data required.
  • Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place before an award will be made.
  • Preclinical and correlative studies are not allowed.
  • Anticipation is that budgets will not exceed $600,000 in direct costs.
  • Period of performance not to exceed 3 years.
Exploration - Hypothesis Development Award

(New for FY16)		 Independent investigators at or above the level of Assistant Professor (or equivalent). All applications submitted in this funding opportunity must address the Biology, Measurement, or Treatment of MS Symptoms.
  • Symptoms may include: Pain, Fatigue, Cognitive Dysfunction, Visual Impairment, Motor Impairment, Impaired Mobility, Loss of Bladder Control, Sexual Dysfunction, Depression, and Anxiety.
Note: Studies of disease-modifying or regenerative therapies that secondarily impact symptoms will not be considered for funding.
  • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.
  • Pre-application (Letter of Intent) submission is required.
  • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
  • Preliminary data is not required.
  • Clinical trials not allowed.
  • Anticipation is that budgets will not exceed $150,000 in direct costs.
  • Period of performance not to exceed 2 years.
Investigator-Initiated Research Award Independent investigators at or above the level of Assistant Professor (or equivalent). All applications submitted in this funding opportunity must address Obstacles to Remyelination in MS.

Note: Projects addressing the mechanisms of demyelination will not be considered for funding.
  • Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.
  • Pre-application submission is required; application submission is by invitation only.
  • Preliminary data is required.
  • Clinical trials not allowed.
  • Anticipation is that budgets will not exceed $600,000 in direct costs.
  • Period of performance not to exceed 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released go to the CDMRP website (https://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications. For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Thursday, May 26, 2022